Zhou L, Xiao H, Chen J
Front Immunol. 2024; 15:1302797.
PMID: 38390329
PMC: 10881679.
DOI: 10.3389/fimmu.2024.1302797.
Pothuraju R, Khan I, Jain M, Bouvet M, Malafa M, Roy H
Cancer Lett. 2024; 587:216704.
PMID: 38360138
PMC: 11257378.
DOI: 10.1016/j.canlet.2024.216704.
Fang Q
Cancers (Basel). 2024; 16(2).
PMID: 38254819
PMC: 10814553.
DOI: 10.3390/cancers16020331.
Qian L, Li N, Lu X, Xu M, Liu Y, Li K
Nat Metab. 2023; 5(7):1159-1173.
PMID: 37337119
DOI: 10.1038/s42255-023-00818-7.
Biswas K, Mohammed A, Sharan S, Shoemaker R
Cancer Sci. 2023; 114(5):1800-1815.
PMID: 36715493
PMC: 10154891.
DOI: 10.1111/cas.15737.
Loss of mismatch repair promotes a direct selective advantage in human stem cells.
Madden-Hennessey K, Gupta D, Radecki A, Guild C, Rath A, Heinen C
Stem Cell Reports. 2022; 17(12):2661-2673.
PMID: 36368329
PMC: 9768573.
DOI: 10.1016/j.stemcr.2022.10.009.
A Human MSH6 Germline Variant Associated With Systemic Lupus Erythematosus Induces Lupus-like Disease in Mice.
Meas R, Nititham J, Taylor K, Maher S, Clairmont K, Carufe K
ACR Open Rheumatol. 2022; 4(9):760-770.
PMID: 35708944
PMC: 9469486.
DOI: 10.1002/acr2.11471.
SLX4 dampens MutSα-dependent mismatch repair.
Guervilly J, Blin M, Laureti L, Baudelet E, Audebert S, Gaillard P
Nucleic Acids Res. 2022; 50(5):2667-2680.
PMID: 35166826
PMC: 8934664.
DOI: 10.1093/nar/gkac075.
Characterization of the Genomic and Immunologic Diversity of Malignant Brain Tumors through Multisector Analysis.
Schaettler M, Richters M, Wang A, Skidmore Z, Fisk B, Miller K
Cancer Discov. 2021; 12(1):154-171.
PMID: 34610950
PMC: 9296070.
DOI: 10.1158/2159-8290.CD-21-0291.
Platinum Complexes in Colorectal Cancer and Other Solid Tumors.
Koberle B, Schoch S
Cancers (Basel). 2021; 13(9).
PMID: 33922989
PMC: 8123298.
DOI: 10.3390/cancers13092073.
Advances in Our Understanding of the Molecular Mechanisms of Action of Cisplatin in Cancer Therapy.
Tchounwou P, Dasari S, Noubissi F, Ray P, Kumar S
J Exp Pharmacol. 2021; 13:303-328.
PMID: 33776489
PMC: 7987268.
DOI: 10.2147/JEP.S267383.
DNA alkylation lesion repair: outcomes and implications in cancer chemotherapy.
Peng Y, Pei H
J Zhejiang Univ Sci B. 2021; 22(1):47-62.
PMID: 33448187
PMC: 7818015.
DOI: 10.1631/jzus.B2000344.
Mechanisms and therapeutic implications of hypermutation in gliomas.
Touat M, Li Y, Boynton A, Spurr L, Iorgulescu J, Bohrson C
Nature. 2020; 580(7804):517-523.
PMID: 32322066
PMC: 8235024.
DOI: 10.1038/s41586-020-2209-9.
Mouse models of colorectal cancer: Past, present and future perspectives.
Burtin F, Mullins C, Linnebacher M
World J Gastroenterol. 2020; 26(13):1394-1426.
PMID: 32308343
PMC: 7152519.
DOI: 10.3748/wjg.v26.i13.1394.
Chromatin remodeling and mismatch repair: Access and excision.
Goellner E
DNA Repair (Amst). 2019; 85:102733.
PMID: 31698199
PMC: 7367450.
DOI: 10.1016/j.dnarep.2019.102733.
Replication stress triggers microsatellite destabilization and hypermutation leading to clonal expansion in vitro.
Matsuno Y, Atsumi Y, Shimizu A, Katayama K, Fujimori H, Hyodo M
Nat Commun. 2019; 10(1):3925.
PMID: 31477700
PMC: 6718401.
DOI: 10.1038/s41467-019-11760-2.
Dose-dependent spatiotemporal responses of mammalian cells to an alkylating agent.
Rancourt A, Sato S, Satoh M
PLoS One. 2019; 14(3):e0214512.
PMID: 30925183
PMC: 6440626.
DOI: 10.1371/journal.pone.0214512.
The properties of Msh2-Msh6 ATP binding mutants suggest a signal amplification mechanism in DNA mismatch repair.
Graham 5th W, Putnam C, Kolodner R
J Biol Chem. 2018; 293(47):18055-18070.
PMID: 30237169
PMC: 6254361.
DOI: 10.1074/jbc.RA118.005439.
An Msh3 ATPase domain mutation has no effect on MMR function.
Edwards Y
BMC Res Notes. 2017; 10(1):616.
PMID: 29178930
PMC: 5702223.
DOI: 10.1186/s13104-017-2939-4.
Suspected Lynch syndrome associated MSH6 variants: A functional assay to determine their pathogenicity.
Houlleberghs H, Goverde A, Lusseveld J, Dekker M, Bruno M, Menko F
PLoS Genet. 2017; 13(5):e1006765.
PMID: 28531214
PMC: 5460888.
DOI: 10.1371/journal.pgen.1006765.